Stock PBYI PUMA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
5.02 USD +2.87% Intraday chart for Puma Biotechnology, Inc. +0.20% +15.94%
Mar. 20 Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise MT
Mar. 20 Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 340.9 408 124.3 196 206 242.2 - -
Enterprise Value (EV) 1 324.2 412.9 158.3 196 206 242.2 242.2 242.2
P/E ratio -4.49 x -6.75 x -4.22 x - 9.62 x 19.4 x 29.7 x 33.5 x
Yield - - - - - - - -
Capitalization / Revenue 1.25 x 1.81 x 0.49 x 0.86 x 0.87 x 1.05 x 1.04 x 1.01 x
EV / Revenue 1.25 x 1.81 x 0.49 x 0.86 x 0.87 x 1.05 x 1.04 x 1.01 x
EV / EBITDA -10,989,610 x -20,028,600 x 10,455,282 x 6,009,876 x - - - -
EV / FCF 15.4 x 561 x 6.02 x -8.59 x 7.67 x 5.26 x 5.15 x 5.77 x
FCF Yield 6.47% 0.18% 16.6% -11.6% 13% 19% 19.4% 17.3%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 38,961 39,762 40,886 46,346 47,571 48,239 - -
Reference price 2 8.750 10.26 3.040 4.230 4.330 5.020 5.020 5.020
Announcement Date 2/20/20 2/25/21 3/3/22 3/2/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 272.3 225.1 253.2 228 235.6 230.6 232.6 239.8
EBITDA -31.02 -20.37 11.89 32.62 - - - -
EBIT 1 -39.1 -30.4 1.3 23.7 32.6 24.4 23.75 16
Operating Margin -14.36% -13.51% 0.51% 10.39% 13.84% 10.58% 10.21% 6.67%
Earnings before Tax (EBT) 1 -75.6 -59.8 -28.8 0.5 22.7 13.4 5.5 -15
Net income 1 -75.6 -60 -29.1 - 21.6 13.45 14.1 6.95
Net margin -27.76% -26.65% -11.49% - 9.17% 5.83% 6.06% 2.9%
EPS 2 -1.950 -1.520 -0.7200 - 0.4500 0.2583 0.1690 0.1500
Free Cash Flow 1 22.07 0.727 20.65 -22.83 26.87 46 47 42
FCF margin 8.11% 0.32% 8.16% -10.01% 11.4% 19.95% 20.21% 17.51%
FCF Conversion (EBITDA) - - 173.7% - - - - -
FCF Conversion (Net income) - - - - 124.39% 342.01% 333.33% 604.32%
Dividend per Share - - - - - - - -
Announcement Date 2/20/20 2/25/21 3/3/22 3/2/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 46.2 55.4 45.7 59.5 57.1 65.7 52.8 54.6 56.1 72.2 49.05 58.8 58.45 64.25
EBITDA - - - - 4.62 - - 7.768 - - - - - -
EBIT 1 -9 6.8 -0.7 12.1 2.393 10 4.4 4.9 8.6 14.8 -7.7 8.9 9 14.2
Operating Margin -19.48% 12.27% -1.53% 20.34% 4.19% 15.22% 8.33% 8.97% 15.33% 20.5% -15.7% 15.14% 15.4% 22.1%
Earnings before Tax (EBT) 1 -44.7 4.4 -3.4 9.5 -0.293 -5.3 1.6 2.3 6 12.8 -11.4 5.8 8.3 10.7
Net income 1 -44.7 4.2 -3.4 9.4 -0.36 -5.6 1.4 2.1 5.8 12.3 -10.2 6.15 6.2 11.25
Net margin -96.75% 7.58% -7.44% 15.8% -0.63% -8.52% 2.65% 3.85% 10.34% 17.04% -20.8% 10.46% 10.61% 17.51%
EPS 2 -1.090 0.1000 -0.0800 0.2100 -0.0100 -0.1200 0.0300 0.0500 0.1200 0.2600 -0.2167 0.0283 0.1360 0.2667
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/4/21 3/3/22 5/5/22 8/4/22 11/3/22 3/2/23 5/4/23 8/3/23 11/2/23 2/29/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - 4.92 34 - - - - -
Net Cash position 16.7 - - - - - - -
Leverage (Debt/EBITDA) - -0.2416 x 2.857 x - - - - -
Free Cash Flow 1 22.1 0.73 20.7 -22.8 26.9 46 47 42
ROE (net income / shareholders' equity) -292% -1,042% - 123% - - - -
ROA (Net income/ Total Assets) -30.6% -25% -12.4% - - - - -
Assets 1 247 239.6 235.2 - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - 0.0200 0.5100 -0.3500 - - - -
Capex 0.31 0.05 - - - - - -
Capex / Sales 0.11% 0.02% - - - - - -
Announcement Date 2/20/20 2/25/21 3/3/22 3/2/23 2/29/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Puma Biotechnology, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
5.02 USD
Average target price
4.333 USD
Spread / Average Target
-13.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PUMA BIOTECHNOLOGY, INC. Stock Puma Biotechnology, Inc.
+15.94% 242M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PBYI Stock
  4. Financials Puma Biotechnology, Inc.